Synthesis of artificial lymphoid tissue with immunological function

Trends in Immunology

Volumn 31, Issue 11, 2010, Pages 422-428

  Kobayashi, Yuka ^a   Watanabe, Takeshi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL13 CHEMOKINE; CYTOKINE; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; RETINOIC ACID RECEPTOR; SCAFFOLD PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; VASCULOTROPIN;

B LYMPHOCYTE; CELL ACTIVITY; CELL TYPE; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; IN VIVO STUDY; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHOCYTE; LYMPHOID CELL; LYMPHOID ORGAN; LYMPHOID TISSUE; MICROENVIRONMENT; NONHUMAN; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TISSUE GRAFT;

ADAPTIVE IMMUNITY; ANIMALS; ARTIFICIAL ORGANS; CHEMOKINES; HUMANS; LYMPHOCYTES; LYMPHOID TISSUE;

EID: 78049264846     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2010.09.002     Document Type: Review

References (83)

1. Mebius R. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 2003, 3:292-303.
2. Fu Y., Chaplin D. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 1999, 17:399-433.
3. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 2006, 6:205-217.
4. Thaunat O., et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14723-14728.
5. Young C.L., et al. Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1984, 27:32-39.
6. Takemura S., et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 2001, 167:1072-1080.
7. Shi K., et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J. Immunol. 2001, 166:650-655.
8. Grabner R., et al. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J. Exp. Med. 2009, 206:233-248.
9. Lotzer K., et al. Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor NF-kappaB signaling. Arterioscler. Thromb. Vasc. Biol. 2010, 30:395-402.
10. Stott D.I., et al. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J. Clin. Invest. 1998, 102:938-946.
11. Salomonsson S., et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum. 2003, 48:3187-3201.
12. Nasr I.W., et al. Tertiary lymphoid tissues generate effector and memory T cells that lead to allograft rejection. Am. J. Transplant. 2007, 7:1071-1079.
13. Drayton D.L., et al. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 2006, 7:344-353.
14. Ruddle N.H., Akirav E.M. Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response. J. Immunol. 2009, 183:2205-2212.
15. Randall T.D., et al. Development of secondary lymphoid organs. Annu. Rev. Immunol. 2008, 26:627-650.
16. Kim M.Y., et al. Function of CD4+CD3- cells in relation to B- and T-zone stroma in spleen. Blood 2007, 109:1602-1610.
17. Kim M.Y., et al. Lymphoid tissue inducer cells: architects of CD4 immune responses in mice and men. Clin. Exp. Immunol. 2009, 157:20-26.
18. Evans I., Kim M.Y. Involvement of lymphoid inducer cells in the development of secondary and tertiary lymphoid structure. BMB Rep. 2009, 42:189-193.
19. Sun Z., et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000, 288:2369-2373.
20. Eberl G., et al. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 2004, 5:64-73.
21. Kim D., et al. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J. Exp. Med. 2000, 192:1467-1478.
22. Yokota Y., et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999, 397:702-706.
23. Glanville S.H., et al. Transplantation of embryonic spleen tissue reveals a role for adult non-lymphoid cells in initiating lymphoid tissue organization. Eur. J. Immunol. 2009, 39:280-289.
24. Cupedo T., et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat. Immunol. 2009, 10:66-74.
25. Buettner M., et al. Stromal cell heterogeneity in lymphoid organs. Trends Immunol. 2010, 31:80-86.
26. Chyou S., et al. Fibroblast-type reticular stromal cells regulate the lymph node vasculature. J. Immunol. 2008, 181:3887-3896.
27. Molenaar R., et al. Lymph node stromal cells support dendritic cell-induced gut-homing of T cells. J. Immunol. 2009, 183:6395-6402.
28. Hammerschmidt S.I., et al. Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. J. Exp. Med. 2008, 205:2483-2490.
29. Iwata M., et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004, 21:527-538.
30. Tomei A.A., et al. Fluid flow regulates stromal cell organization and CCL21 expression in a tissue-engineered lymph node microenvironment. J. Immunol. 2009, 183:4273-4283.
31. Peduto L., et al. Inflammation recapitulates the ontogeny of lymphoid stromal cells. J. Immunol. 2009, 182:5789-5799.
32. Fletcher A.L., et al. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J. Exp. Med. 2010, 207:689-697.
33. Cohen J.N., et al. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J. Exp. Med. 2010, 207:681-688.
34. Dejardin E., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002, 17:525-535.
35. Vondenhoff M.F., et al. LTbetaR signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen. J. Immunol. 2009, 182:5439-5445.
36. Bista P., et al. TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor. J. Biol. Chem. 2010, 285:12971-12978.
37. Xie P., et al. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007, 27:253-267.
38. GeurtsvanKessel C.H., et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 2009, 206:2339-2349.
39. Reijmers R.M., et al. Impaired lymphoid organ development in mice lacking the heparan sulfate modifying enzyme glucuronyl C5-epimerase. J. Immunol. 2010, 184:3656-3664.
40. Rodgers K.D., et al. Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators. Dev. Dyn. 2008, 237:2622-2642.
41. Johnson Z., et al. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 2005, 16:625-636.
42. Fukuyama S., et al. Cutting edge: Uniqueness of lymphoid chemokine requirement for the initiation and maturation of nasopharynx-associated lymphoid tissue organogenesis. J. Immunol. 2006, 177:4276-4280.
43. Bai Z., et al. CXC chemokine ligand 12 promotes CCR7-dependent naive T cell trafficking to lymph nodes and Peyer's patches. J. Immunol. 2009, 182:1287-1295.
44. Manzo A., et al. CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. Am. J. Pathol. 2007, 171:1549-1562.
45. van de Pavert S.A., et al. Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nat. Immunol. 2009, 10:1193-1199.
46. Ansel K.M., et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000, 406:309-314.
47. Luther S.A., et al. Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. J. Exp. Med. 2003, 197:1191-1198.
48. Reif K., et al. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 2002, 416:94-99.
49. Fan L., et al. Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J. Immunol. 2000, 164:3955-3959.
50. Luther S.A., et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 2002, 169:424-433.
51. Hjelmstrom P., et al. Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am. J. Pathol. 2000, 156:1133-1138.
52. Meier D., et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 2007, 26:643-654.
53. Drayton D.L., et al. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J. Exp. Med. 2003, 197:1153-1163.
54. Akita M., et al. Morphology of capillary-like structures in a three-dimensional aorta/collagen gel culture. Ann. Anat. 1997, 179:127-136.
55. Niklason L.E., et al. Functional arteries grown in vitro. Science 1999, 284:489-493.
56. Yu X., et al. Bioreactor-based bone tissue engineering: the influence of dynamic flow on osteoblast phenotypic expression and matrix mineralization. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11203-11208.
57. Lutolf M.P., et al. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat. Biotechnol. 2003, 21:513-518.
58. Teng Y.D., et al. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3024-3029.
59. Yu X., Bellamkonda R.V. Tissue-engineered scaffolds are effective alternatives to autografts for bridging peripheral nerve gaps. Tissue Eng. 2003, 9:421-430.
60. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 2005, 23:47-55.
61. Griffith L.G., Swartz M.A. Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 2006, 7:211-224.
62. Stachowiak A.N., Irvine D.J. Inverse opal hydrogel-collagen composite scaffolds as a supportive microenvironment for immune cell migration. J. Biomed. Mater. Res. A 2008, 85:815-828.
63. Suematsu S., Watanabe T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat. Biotechnol. 2004, 22:1539-1545.
64. Richardson T.P., et al. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 2001, 19:1029-1034.
65. Sun Q., et al. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm. Res. 2005, 22:1110-1116.
66. Chen R.R., et al. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm. Res. 2007, 24:258-264.
67. Thompson E.D., et al. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 2010, 207:1791-1804.
68. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
69. Flavell R.A., et al. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 2010, 10:554-567.
70. Okamoto N., et al. Artificial lymph nodes induce potent secondary immune responses in naive and immunodeficient mice. J. Clin. Invest. 2007, 117:997-1007.
71. Pan W.R., et al. Senile changes in human lymph nodes. Lymphat. Res. Biol. 2008, 6:77-83.
72. Willfuhr K.U., et al. Splenic autotransplantation provides protection against fatal sepsis in young but not in old rats. J. Pediatr. Surg. 1992, 27:1207-1212.
73. Grikscheit T.C., et al. Tissue-engineered spleen protects against overwhelming pneumococcal sepsis in a rodent model. J. Surg. Res. 2008, 149:214-218.
74. Giese C., et al. A human lymph node in vitro-challenges and progress. Artif. Organs 2006, 30:803-808.
75. Butler M.O., et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin. Cancer Res. 2007, 13:1857-1867.
76. Ugel S., et al. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res. 2009, 69:9376-9384.
77. Ito M., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
78. Shultz L.D., et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005, 174:6477-6489.
79. Ishikawa F., et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 2005, 106:1565-1573.
80. Shultz L.D., et al. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
81. Saito Y., et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010, 28:275-280.
82. Zhang L., et al. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 2007, 109:2978-2981.
83. Legrand N., et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 2009, 6:5-9.